ERBB2 and non-small cell lung carcinoma: Negrao et al. reported on two different cohorts of unselected NSCLC patients with actionable alterations including activating HER2 mutations (MD Anderson Cancer Center [MDACC], n = 15; Flatiron Health-Foundation Medicine Clinico-Genomic Database [CGDB], n = 28) [63].